6. Феськов А. М., Сомова Е. В. Особенности микроокружения ооцитов и морфологии эмбрионов у женщин с СПКЯ, Харьков, 2010 г.
Практическое руководство по лечению женского бесплодия, обусловленного крушениями процесса овуляции/ Т.А. Назаренко и др. Москва. 2005.-С. 5-8.
Фанченко Н.Д. Лабораторная диагностика нарушений центральной регуляции репродуктивной системы/ Н.Д. Фанченко Проблемы репродукции. 2001.-№ 1.-С. 100-103.
Asuncion М, Caivo R M , San Mil Ian JL, Sancho J. A vila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000; 85:2434-8.
Azziz R. Woods KS, Reyna R. Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89:2745-9.
Diamanti-Kandarakis E, Kouli C'R, Bergiele AT. Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999; 84:4006-11.
March W A . Moore VM , Willson KJ, Phillips DI, Norm an RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a com m unity sample assessed under contrasting diagnostic criteria. Hum Reprod. Hum Reprod. 2010 Feb; 25(2):544-51.
13. Moran C, Tena G, Moran S, Ruiz P, Reyna R, X. D. Prevalence of polycystic ovary syndrome and related disorders in Mexican women. Gynecol Obstet Invest. 2010; 69:274-80.
14. Yildiz BO, Bozdag G, Yapici Z, Esinler I. Yarali II. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Mum Reprod. 2012 Oct; 27(10):3067-73.
15. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens КС, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients .1 Clin Endocrinol Metab. 2004 Feb;89(2):453-62.
16. Azziz R, Carmina E, Devvailly D, Diam anti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norm an RJ, Taylor A E, Witchel SF I he Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009 Feb;91(2):456-88.
17. Carmina E, Rosato F, Janni A, Rizzo M , Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism J Clin Endocrinol Metab. 2006 Jan; 91(1 ):2-6.
Hardiraan P, Pillay ОС, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003; 361:1810.
Gadducci A, Gargini A, Pal la E, et al. Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol 2005; 20:200.
Glucose intolerance in polycystic ovary syndrome - a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007 Dec; 92(12):4546-56.
Wild S, Pierpoint T, McKeigue P, and Jacobs FI. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin. Endocrinol. 2000 52: 595-600
Randeva H S, Tan BK , Weickert MO, et al. C ardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012; 33:812.
Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens J. Haseltine Haseltine F, Haseltine G, eds. Polycystic Ovary Syndrome, ls d . Oxford, England: Blackwell Scientific; 1992:377-384
Rotterdam ESM RE/ASRM -Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004: 19:41-7.
Azziz R, Carmina J2, Dewailly D et al. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006 Nov; 91(11):4237-45.
http://prevention.nih.gov/workshops/2012/pcos/docs/FinalR eport.pdf
Escobar-Morreale IIF1, Carmina E, Dewailly D et al. E pidemiology, diagnosis and management of hirsutism : a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012 Mar-Apr; 18(2): 146-70.
Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM , Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013 Dec; 98 (12):4565-9.
Cheewadhanaraks S, Peeyananjarassri K, Cboksuchat С Clinical diagnosis of hirsutism in Thai women. J Med Assoc Thai. 2004 M ay;87(5):459-63.
Yildiz BO. Bolour S, Woods K, Moore A, Azziz R. Visually scoring hirsutism. HumReprod Update 2010; 16:51-64.
Karrer-Voegeli S, Rev F, Reymond MJ, Meuwly JY , Gaillard RC, Gomez F. Androgen dependence of hirsutism , acne, and alopecia imvomen: retrospective analysis of 228 patients investigated for hyperandrogenism . Medicine (Baltim ore). 2009; 88:32-45.
Rosner W. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007 Feb: 92(2):405-13,
Stanczyk F.Z. Diagnosis of hyperandrogenism : Biochemical criteria Best Practice & Research Clinical Endocrinology & Metabolism 2006 Vol. 20, No. 2, pp. 177-191.
Medical eligibility criteria for contraceptive use. W HO: 4th ed. 2010
Consensus on infertility treatment related to polycystic ovary syndrome. Thessaloniki ESH R E/A SR M -Sponsored PCOS Consensus Workshop Group. H um Reprod. 2008 Mar; 23(3):462-77.
Imam B l, Eijkemans M J. te Velde ER et al. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril. 2002 Jan;77( 1 ):9 1 -7.
N IH /N IC H D Reproductive Medicine Network. Effect of letrozole versus clomiphene on live birth in women with anovulatory infertility due to polycystic ovary syndrome (PCOS): a randomized double- blind multicenter trial. Fertil Steril. 2013; 100
Farquhar C, Brow n J, Marjoribanks J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2012 Jun 13; 6:C D 001122.
Bayram N , vanWely M, Kaaijk EM , Bossuyt PM , van derVeen F. Using an electrocautery strategy or recombinant follicle stim ulatinghorm one to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ 2004; 328:192
Mohammed E. Hyperprolactenaemia after laparoscopic ovarian drilling: an unknown phenomenon. Reprod Endocrin 2005;3:3.
American Society for Reproductive Medicine. (2011). Frequently asked questions about infertility. Retrieved December 22, 2011,
-
ACOG. (2011). Polycystic ovary syndrome. Retrieved May 10, 2012, from (PDF - 73 KB)
-
Moran, L. J., Pasquali, R., Teede, H. J., Hoeger, K. M., & Norman, R. J. (2009). Treatment of obesity in polycystic ovary syndrome: A position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertility and Sterility, 92, 1966–1982.
-
Legro, R. S. (2007). Pregnancy considerations in women with polycystic ovary syndrome. Clinical Obstetrics and Gynecology, 50, 295–304.
-
Kiddy, D.S., Hamilton-Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M.J., et al. (1992). Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clinical Endocrinology (Oxford), 36, 105-111.
-
National Cancer Institute. (2006). Oral contraceptives and cancer risk: Questions and answers. Retrieved December 22, 2011,
-
Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011). Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. Nature Reviews Endocrinology, 7, 219–231.
-
Johnson, N. (2011). Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome—A meta-analysis of randomised trials. Australian and New Zealand Journal of Obstetrics & Gynaecology, 51, 125–129.
-
Vause, T. D., Cheung, A. P., Sierra, S., Claman, P., Graham, J., Guillemin, J. A., et al.; Society of Obstetricians and Gynecologists of Canada (2010). Ovulation induction in polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Canada, 32, 495–502.
-
U.S. Food and Drug Administration (FDA). (2000). VANIQATM (eflornithine hydrochloride) cream, 13.9%. Retrieved December 22, 2011
He, D., & Jiang, F. (2011). Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. Reproductive Biomedicine Online, 23, 91–96.
-
FDA. (2010). Femara (letrozole) tablets: Highlights of prescribing information. Retrieved December 22, 2011,
Bielah К. M. Amenorrhea/ K.M.Bielak И Medicine Journal. 2001. Vol. 2.- P. 125-132.
August 2002, Washington, DC. / ZT Bloomgarden II Diabetes Care.
Central Adiposity Determines Prevalence Differences of the Metabolic Syndrome. / C. Lorenzo, M. Serrano-Rios, M. T. Martinez-Larrad et al.ll Obes. Res.-2003.-Vol. 11.-N.12.-P. 1480-1487.
Kidson W. Polycystic ovary syndrome: a new direction in treatment/ W.Kidson IIMJA. 2005. - Vol. 169. - P. 537-540.
|
